Currently, patients suffering from multiple sclerosis (MS), a chronic demyelinating disorder of the CNS, must be injected with medication to provide modest relief for their symptoms. Five orally available therapies are being evaluated in phase II/III clinical trials. If these therapies prove safe and tolerable, oral compounds may improve patient endorsement and compliance. Fingolimod, a novel immunosuppressant, significantly lowered annual relapse rates in phase II/III trials. Laquinimod, an immunomodulator, reduced the cumulative number of active lesions at the highest dose tested (0.6 mg/d) in a phase II trial. Cladribine, another immunomodulator, reduced annual relapse rates by >50% and gadolinium-positive lesions by >70% at both doses tested in a phase III trial. Oral fumarate, with immunomodulatory and antioxidant properties, also lowered the number of lesions in a phase II trial. Finally, teriflunomide, an immunomodulator, significantly reduced MRI lesion activity and reduced annual relapse rates in a phase II trial. In this report, we weigh the beneficial outcomes of these compounds against their risks of adverse effects.
Pharmacology, Toxicology and Pharmaceutical Science
5
7%
Neuroscience
4
5%
Unspecified
3
4%
Other
7
9%
Unknown
14
19%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 November 2016.
All research outputs
#4,525,601
of 33,992,632 outputs
Outputs from Neurology
#7,851
of 26,125 outputs
Outputs of similar age
#23,931
of 233,406 outputs
Outputs of similar age from Neurology
#22
of 114 outputs
Altmetric has tracked 33,992,632 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 26,125 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.7. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 233,406 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 114 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.
